Arcadia Biosciences
RKDA on Nasdaq. Market value $525,208.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
None of the long-term investors we follow own it. 16 funds in all.
Largest holders overall
- HRT Financial LP$60,000New
- Citadel Advisors$16,120New
- Virtu Financial$15,000New
- StoneX Group$11,259New
- Geode Capital Management$10,957Cut
- XTX Topco$10,509New
- State Street$8,248
- Jane Street Group$6,957New
- Vanguard Capital Management$6,548
- SBI Securities$81
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- MJL Manager LLCPassive investorat least 15.7%(filed with 2 related holders)Since 25 September 2026
- Armistice Capital, LLCPassive investorat least 10.0%0.0 pts(filed with 1 related holder)Since 30 September 2026
- SABBY MANAGEMENT, LLCPassive investorat least 4.9%(filed with 2 related holders)Since 31 December 2024
| Holder | Stake | Since | |
|---|---|---|---|
MJL Manager LLC Passive investor | at least 15.7% (filed with 2 related holders) | 25 September 2026 | |
Armistice Capital, LLC Passive investor | at least 10.0%0.0 pts (filed with 1 related holder) | 30 September 2026 | |
SABBY MANAGEMENT, LLC Passive investor | at least 4.9% (filed with 2 related holders) | 31 December 2024 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought or sold on the open market in the last 12 months.
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
2 serious warning signs in Arcadia Biosciences’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Mar 2026, plus the 10-Q filed 12 Nov 2026 and 9 later 8-Ks.
Doubt it can keep going
SeriousThe company or its auditor warned it may not have enough money to last the next year.
“With cash and cash equivalents of $ 2.8 million as of September 30, 2026, the Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern.”
Show the full paragraph
With cash and cash equivalents of $ 2.8 million as of September 30, 2026, the Company believes that its existing cash and cash equivalents will not be sufficient to meet its anticipated cash requirements for at least the next 12 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
From the 10-Q filed 12 November 2026, Part I, Item 1. Financial Statements. Read it in the filing
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our President and Chief Executive Officer and our Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level, as a result of the material weaknesses in our internal control over financial reporting as described below.”
Show the full paragraph
In connection with our chief executive officer’s and chief financial officer’s review of the disclosure controls and procedures for our Annual Report on Form 10-K for the year ended December 31, 2025, our management concluded that there were material weaknesses in our disclosure controls and procedures as described below. Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, our President and Chief Executive Officer and our Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level, as a result of the material weaknesses in our internal control over financial reporting as described below. Notwithstanding these material weaknesses, management concluded that our consolidated financial statements included in this Quarterly Report on Form 10-Q fairly present, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in conformity with U.S. GAAP.
From the 10-Q filed 12 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
Changed auditor
Worth knowingThe company changed its auditor (the firm that checks its books) in the last two years.
“On March 30, 2026, the audit committee (the “Audit Committee”) of the board of directors of Arcadia Biosciences, Inc. (the “Company”) dismissed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm.”
From an 8-K filed 3 April 2026: Change of auditor. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.